The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Of course they will have talked to Az - even if through back channels - and after those chats - the ex AZ Ceo expert in the field left because “of a better salary” … hmmm and you say that’s not indicative
If 004 had legs she would have raised enough to get paid - It was the biggest bull market for biotech ever seen
I get where you are coming from FX, I'm just conscious that some discussions here can only be circular.
For example, lets look at the query 'we're not even talking to AZ yet, why? '
The first logical discussion points, how do you know they are not talking to AZ? They aren't going to tell us if they are as it would be commercially sensitive. Also why would they not talk to Merck? Why specifically AZ?
So following that, if they are not talking to AZ, why not? Well, they have always phrased it as ' If the patent applications on these new forms are granted....' because they wouldn't have anything to offer AZ (or Merck)
So you could say in answer to your question, they told you they wouldn't be talking to anyone yet.
As I've said before its a Schrodingers Cat of a situation, they could be in talks, or they could not be in talks, we don't know until we find out.
Same with 'what has DG been doing' you won't find out till its conclusion and I wouldn't expect to hear beforehand.
I was already resigned to that Soup. No reason we can't discuss it though.
Fair enough FX, I guess you’ll just have to accept you’ll have to wait get the answers to your questions when the company is willing to tell you.
Thanks for the suggestion Soup. Unfortunately, like you, I will be too far away and can't break current commitments.
Fx, I’d suggest you attend the AGM, you can ask them your questions in person then.
I do see the arguments for progressing NXP004 Mars, the question is whether or not we have the stability to wait for that to happen. It is all down to Maddy and Julian now. They are part time NED's who are probably working for others and whose priorities could shift at any time.
I would feel alot better if we either had news that the team had been strengthened enough to absorb or dispel the risk of future personnel shocks or that we were at least talking to interested partners.
FX from the Rob David interview
“ And then another issue to address, final on the business development front is the mindset of the folks that you may be sitting around the table or across the table from. We’re seeing a really challenging environment for small mid-cap biotech. Science is advancing tremendously, but certainly amongst the smaller companies in the public sphere, it’s been very difficult. And the debate inevitably becomes whether or not the willingness to reach across that table and shake hands, the bid-ask spread. Has that mindset adjusted in any way? I think during the first quarter call, you had commented that you had not necessarily seen some of that shift. Tick-tock, we’re further along. Where are things at now?
Rob Davis
I would tell you that as of now the world has not meaningfully shifted from where we were. We continue to not see a meaningful change yet. We’re going to have to see what happens, obviously, as the market continues to be down and for a sustained period of time, and as cash becomes tighter for a lot of these companies, I do think it could evolve, but we’re not seeing it. I think there’s enough cash still in the system for a lot of the companies that they have time to kind of wait. So, we’ll have to see how it plays out over the rest of the year.”
Can see why a bio better 004 would help.
The price is still 0.35p, almost 10 times lower than when Brindley took the reigns.
OK, so they've tried to take the sting out of Brindley & Riddells failure to deliver the full data package that was promised for the end of last year (plus the damage that both departures have done), by using encouraging words but it's still just warm air at present. We are still in a worse position than we were before Riddell's last RNS came out. We now have to wait for the durability tests to be done all over again.
Nothing has changed and we're not even talking to AZ yet, why? Is there any form of discussion going on? What has Gooding been doing since he started being paid as a BD consultant?
‘We believe that NXP004 has considerable commercial potential and the work we are now undertaking is designed to formulate our lead co-crystals towards a product form suitable for human use.’
Scratch that… 2 days left this week. Forgot it’s only Wednesday.
Not a bad day all round, as we end the week we know more about the strategy moving forwards than we have done for a long time.
Just one more day left this week....
I see. Sorry, thought you were being sarcastic.
Old habits lol.
Not at all. Encouraging people to buy and join the herd.
ATB
Why would they do that Chablard?
Are you suggesting they are trying to disguise the fact that people may be selling? To what end?
Love the way the mm's are spreading the buys around by splitting them into smaller lots to give the page a blue look
(28.57%) Spread
Yep, and after 2 bits of decent news, there will be buy orders to fill now, so spread will stay wide to make the subserfuge easier, imo.
Have to admit the MM's playing a blinder at the moment, basically anyone who bought this morning after 08.02am can only sell at a loss.
Going to be the test now, punters who bought this morning now facing the choice of whether to hold or not. Someone just sold their 421k three hours after buying it at 0.47
Buying stalled. They'll need to close that spread to attract more buyers. A few fingers burnt?
What is interesting in the Merck CEO interview was he said further negotiations were expected later this year
Might be a big jump bit the sell price is staying low. A big split in the buy/sell price
As always, the time to buy was last week, when most were whining, moaning and wetting their pants.